The Pharma Data
MAY 2, 2023
a clinical trial data collection company, since 2021. From 2008 to 2021, Mr. Bonello held roles of increasing responsibility at Nasdaq-listed PRA Health Sciences, Inc., Mr. Bonello previously served as Senior Vice President, Accounting and Corporate Controller for PRA, after having joined the company in March 2008.
The Pharma Data
DECEMBER 10, 2020
Spending several years with Sanofi in Paris, France as a Global safety officer, he then relocated to New Jersey, USA to work in Early and Late Stage Clinical Development in Immunology, when he became the Global Project Head of Dupixent, a medicine that has revolutionized the field of allergic and atopic diseases.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
MARCH 2, 2021
This new collaboration builds on the positive experience from previous partnerships with Gubra and combines Gubra’s proprietary streaMLine platform and expertise in obesity and peptide chemistry with Boehringer Ingelheim’s expertise in lead optimization and clinical development. Financial terms of the new agreement are not disclosed.
Conversations in Drug Development Trends
APRIL 5, 2024
Observed annually on the last day of February since 2008, Rare Disease Day has grown into a global movement for raising awareness, promoting research, and advocating for improved access to rare disease treatments and support services. For others, this rare day is aptly the day we honor rare disease communities.
Metabolite Tales Blog
JANUARY 26, 2023
What’s clear from the table is the lack of major metabolism via CYP2D6, despite this isoform being responsible for clearance of at least 20% of compounds in current clinical use (Maréchal et al., References Iversen et al., Drug metabolism and drug transport of the 100 most prescribed oral drugs. Basic Clin Pharmacol Toxicol. Br J Pharmacol.
Drug Target Review
SEPTEMBER 26, 2023
1-4 This approach saves time, money, and resources, and ultimately leads to safer medicines going forward to the clinic. CNS-related issues account for nearly a quarter of failures during clinical development, a phase where consequences are high in terms of resources and patient impact. 2008 Mar;153 Suppl 2(Suppl 2):S1-209.
The Pharma Data
DECEMBER 17, 2020
Cadavid will be responsible for the strategy, direction and execution of the company’s clinical development programs. Prior to Fulcrum, Cadavid held several leadership positions at Biogen, including Senior Medical Director of the multiple sclerosis clinical development group.
Expert insights. Personalized for you.
40 
Let's personalize your content